Prostate Cancer
Advertisement
Dr. Keizman showcases his research on using Decipher for early prostate cancer for USA versus non-USA populations.
Dr. Ghoreifi characterizes the activity of inflammasome genes and their association with oncological outcomes in PC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Radiotherapy may reduce distant metastasis risk in high-risk prostate cancer compared to surgery, according to new study.
Dr. Ciuro previews the potential practice-changing research in prostate, bladder, and kidney cancers from ASCO GU 2025.
C2D1 ctDNA fraction may be more strongly associated with rPFS and OS than baseline ctDNA fraction.
In 53.3% of cases, PSMA PET positively identified bone disease despite negative findings on bone scintigraphy.
Patients with mHSPC who are younger, have a high BMI, or have low-volume disease may benefit more from treatment with ARPIs.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on TALAPRO-2, studies on oligometastatic disease, and more.
Patients with very high-risk disease saw greater benefit from long-term ADT use compared to those with high-risk disease.
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.